Clinical Trial

TARGET BP I Clinical Trial

Study acronym: TARGET BP I
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 3, 2023 (before its estimated December 2023 completion). Its status may not reflect the trial's current state.
Summary
The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group (without renal denervation - no alcohol infusion). Subjects will be randomized in a 1:1 fashion to treatment versus sham control via central randomization.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2016-09-20; most recent amendment 2024-07-16.
Status change: Recruiting → Active, Not Recruiting 2023-04-06
Status change: Not Yet Recruiting → Recruiting 2019-07-23
Trial Details
NCT Number NCT02910414
Lead Sponsor Ablative Solutions, Inc.
Conditions Hypertension
Enrollment 300 participants
Start Date 2019-07-22
Primary Completion 2023-12 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2023-10-03